Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Clinical and Translational Neurology"
DOI: 10.1002/acn3.700
Abstract: To compare 2‐year effectiveness and discontinuation of natalizumab (NTZ) versus fingolimod (FTY) and dimethyl fumarate (DMF) in the treatment of multiple sclerosis (MS). read more here.
Keywords: treatment; versus fingolimod; multiple sclerosis; dimethyl fumarate ... See more keywords